Postmortem Methamphetamine Evidence: A Litigation Checklist

By Okorie Okorocha, J.D., M.S., M.S.

For attorneys: A postmortem methamphetamine number should not be treated as a direct measurement of the concentration circulating at the moment of death. Sampling site, redistribution, tolerance, disease, co-intoxicants, and case history can determine whether the number supports intoxication, contribution, incidental exposure, or no reliable concentration-based conclusion.

Why the reported number may have changed

After death, methamphetamine can move between tissue reservoirs and blood. Published studies report differences among heart blood, peripheral blood, vitreous humor, liver, lung, myocardium, and other matrices. The result may also change with the interval before collection and the exact method used to obtain the specimen.

This does not mean every postmortem methamphetamine result is unreliable. It means the proponent must identify the specimen and explain how postmortem processes were considered before using the number to support cause, contribution, behavior, or timing.

Twelve questions before calling the concentration fatal

1. What exact specimen was tested? “Blood” is incomplete. Identify the vessel, side, cardiac chamber, or cavity.
2. How was it collected? Determine whether an intact vessel was isolated, whether the sample was obtained by blind stick, and whether organs had been moved or removed.
3. When was it collected? Establish the interval from death to refrigeration, autopsy, sampling, accession, and analysis.
4. Was peripheral blood available? If only central blood was tested, ask why peripheral blood was absent and what limitation the laboratory applied.
5. Were multiple sites compared? A central-peripheral comparison may reveal site variation, but the ratio still requires case-specific interpretation.
6. Which tissues and fluids were retained? Ask about vitreous, urine, liver, lung, myocardium, brain, muscle, bile, and gastric contents.
7. Were both methamphetamine and amphetamine quantified? The metabolite relationship can add context but is not a universal clock.
8. Was enantiomer analysis performed? A non-chiral result does not distinguish more potent d-methamphetamine from every possible l-methamphetamine source.
9. What other substances were present? Alcohol, opioids, sedatives, stimulants, medications, and metabolites may alter the causal analysis.
10. What disease or injury was documented? Cardiovascular disease, hyperthermia, trauma, asphyxia, infection, and other pathology may compete with or interact with drug exposure.
11. What evidence supports tolerance or recent abstinence? A numerical concentration cannot reveal an individual’s tolerance by itself.
12. What scientific authority supports the opinion? Require the expert to connect the specific facts to a validated method, not merely cite a broad “lethal range.”

Published averages are not correction factors

One 20-case study reported central methamphetamine concentrations higher than peripheral concentrations in every case. A later 18-case series reported an average central-to-peripheral ratio of 1.61. A three-case paired study reported postmortem peripheral concentrations averaging approximately 1.51 times the antemortem concentrations.

Those results support the existence of postmortem change. They do not authorize subtracting a fixed percentage or dividing every heart result by 1.61. Each figure came from a particular sample, population, collection method, and postmortem interval, with case-to-case variation.

The mechanism itself may be disputed

Some investigators emphasized movement between myocardium and heart blood. Other work proposed rapid release from the lungs through pulmonary veins into the left heart during the early postmortem period. A detailed single-cadaver study later suggested that methamphetamine may decrease in some venous sites, including the femoral vein, through diffusion across vessel walls.

These differences matter in litigation. An expert who says “redistribution always raises the heart result” or “femoral blood is unchanged” should identify the study and the conditions that make the statement applicable to the actual case.

Fatal and incidental concentrations overlap

Quigley and colleagues published cases showing wide overlap between concentrations in deaths attributed to methamphetamine intoxication and cases where methamphetamine was incidental or another cause was identified. In that series, deaths attributed solely to methamphetamine ranged from 102 to 17,662 ng/mL, while incidental findings ranged from 91.5 to 9,105 ng/mL.

The point is not that concentration is irrelevant. The point is that there is no single concentration that independently proves cause of death across all individuals and circumstances. A low number can matter in a susceptible person or mixed-drug death, while a much higher number can occur in a tolerant person who dies from trauma or disease.

Records counsel should obtain

• scene, witness, medical-response, and resuscitation records;
• last-known-use, route, quantity, tolerance, and abstinence history;
• autopsy report, photographs, histology, and organ weights;
• specimen diagram, collection notes, tube labels, and chain of custody;
• refrigeration, transport, storage, thaw, and analysis timeline;
• complete specimen inventory and retention/disposition records;
• screening and confirmation methods, including chiral testing;
• validation, calibration, controls, blanks, chromatograms, integrations, and audit trail;
• measurement uncertainty, dilution, repeat-analysis, and reporting records;
• the laboratory’s postmortem interpretation and sampling policies.

Deposition and cross-examination questions

• What is the evidence that this concentration reflects blood at the moment of death?
• What is the exact anatomical source, and where is that documented?
• Was the sample collected from an isolated vessel or by blind stick?
• Which published study most closely matches this specimen and interval?
• What was the range—not only the mean—of the cited central-to-peripheral ratios?
• Did the expert apply a fixed redistribution factor? If so, where was it validated for this case?
• What competing cause of death was considered and how was it excluded?
• What role did tolerance, medical disease, trauma, temperature, and co-intoxicants play?
• Could the methamphetamine be contributory or incidental rather than independently fatal?
• What additional specimens could have tested the opinion?

Frequently asked questions

Does heart blood overstate methamphetamine?

It may be higher than peripheral blood, and published case series support that concern. The amount of difference varies, and the exact heart chamber and collection conditions matter.

Is femoral blood immune from redistribution?

No. It is generally preferred, but postmortem interval, diffusion, collection technique, contamination, and body condition can still affect it.

Can a “lethal range” prove cause of death?

No. Published fatal, contributory, and incidental concentrations overlap. The concentration must be integrated with pathology, history, circumstances, other substances, and specimen quality.

Can an expert reconstruct the antemortem concentration?

Not reliably from one postmortem value using a universal multiplier. A paired antemortem specimen or multiple well-documented postmortem matrices may provide stronger evidence, but limitations remain.

Bottom line

A postmortem methamphetamine opinion should explain the specimen, the postmortem processes, the alternative causes, and the uncertainty—not simply compare one number with a reference table.

For the underlying scientific discussion, see Postmortem Methamphetamine Redistribution: Why Sampling Site Changes the Result. For related representation and expert-review information, see Methamphetamine Toxicology Lawyer and Expert Case Review.

Selected scientific sources

• Pélissier-Alicot AL, Gaulier JM, Champsaur P, Marquet P. Mechanisms underlying postmortem redistribution of drugs: a review. Journal of Analytical Toxicology. 2003;27:533–544.
• Barnhart FE, Fogacci JR, Reed DW. Methamphetamine—a study of postmortem redistribution. Journal of Analytical Toxicology. 1999;23:69–70.
• McIntyre IM, Hamm C, Bader E. Postmortem methamphetamine distribution. Journal of Forensic Research. 2011;2:122. doi:10.4172/2157-7145.1000122.
• McIntyre IM, Nelson CL, Schaber B, Hamm CE. Antemortem and postmortem methamphetamine blood concentrations: three case reports. Journal of Analytical Toxicology. 2013;37:386–389. doi:10.1093/jat/bkt040.
• Quigley K, Shanks K, Behonick G, Terrell A. A guide for the interpretation of postmortem methamphetamine findings. Journal of Forensic Toxicology & Pharmacology. 2014;3:2. doi:10.4172/2325-9841.1000117.
• Wurita A, Hasegawa K, Minakata K, et al. Postmortem redistribution of methamphetamine and amphetamine in multiple human matrices. Forensic Toxicology. 2016.

Educational information only. This article is not legal advice or a case-specific expert opinion.